Ra Larson

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. pmc A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
    Eunice S Wang
    Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Hematol Oncol 5:71. 2012
  2. doi request reprint Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
    R A Larson
    University of Chicago, Chicago, IL, USA
    Leukemia 26:2197-203. 2012
  3. pmc Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
    Azra Raza
    University of Massachusetts Medical Center, Worcester, MA, USA
    J Hematol Oncol 2:20. 2009
  4. ncbi request reprint Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine
    Richard A Larson
    Hematologic Malignancies Program, Section of Hematology Oncology, Department of Medicine, Cancer Research Center, The University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 34:S13-20. 2007
  5. ncbi request reprint Management of acute lymphoblastic leukemia in older patients
    Richard A Larson
    Department of Medicine and the Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
    Semin Hematol 43:126-33. 2006
  6. doi request reprint Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
    Richard A Larson
    University of Chicago, MC 2115, 5841 S Maryland Ave, Chicago, IL 60637, USA
    Blood 111:4022-8. 2008
  7. doi request reprint Allogeneic hematopoietic cell transplantation for adults with ALL
    Ra Larson
    Department of Medicine and Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
    Bone Marrow Transplant 42:S18-S24. 2008
  8. ncbi request reprint Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
    Richard A Larson
    Department of Medicine and Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Best Pract Res Clin Haematol 20:29-37. 2007
  9. pmc Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia
    Richard A Larson
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Chem Biol Interact 184:21-5. 2010
  10. ncbi request reprint Myelodysplasia: when to treat and how
    Richard A Larson
    Department of Medicine and Cancer Research Center, University of Chicago Pritzker School of Medicine, MC 2115, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Best Pract Res Clin Haematol 19:293-300. 2006

Detail Information

Publications85

  1. pmc A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
    Eunice S Wang
    Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Hematol Oncol 5:71. 2012
    ..This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and its effects on the incidence of clinically significant thrombocytopenic events (CSTEs) in lower risk MDS patients receiving lenalidomide...
  2. doi request reprint Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
    R A Larson
    University of Chicago, Chicago, IL, USA
    Leukemia 26:2197-203. 2012
    ..Nilotinib continues to demonstrate superior efficacy in all key response and outcome parameters compared with imatinib for the treatment of patients with newly diagnosed CML-CP...
  3. pmc Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
    Azra Raza
    University of Massachusetts Medical Center, Worcester, MA, USA
    J Hematol Oncol 2:20. 2009
    ..In phase 2, ezatiostat was administered on 2 dose schedules: 600 mg/m2 IV on days 1 to 5 or days 1 to 3 of a 21-day treatment cycle...
  4. ncbi request reprint Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine
    Richard A Larson
    Hematologic Malignancies Program, Section of Hematology Oncology, Department of Medicine, Cancer Research Center, The University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 34:S13-20. 2007
    ..The rationale, pharmacology, and clinical experience to date with these agents in the treatment of patients with refractory acute leukemia are reviewed, with a highlight on ALL...
  5. ncbi request reprint Management of acute lymphoblastic leukemia in older patients
    Richard A Larson
    Department of Medicine and the Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
    Semin Hematol 43:126-33. 2006
    ..Philadelphia (Ph) chromosome (BCR/ABL)-positive ALL is particularly common among older patients. The availability of specific tyrosine kinase inhibitors is changing the prognosis for this challenging subset...
  6. doi request reprint Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
    Richard A Larson
    University of Chicago, MC 2115, 5841 S Maryland Ave, Chicago, IL 60637, USA
    Blood 111:4022-8. 2008
    ..These results suggest that an adequate plasma concentration of imatinib is important for a good clinical response. This study is registered at http://clinicaltrials.gov as NCT00333840...
  7. doi request reprint Allogeneic hematopoietic cell transplantation for adults with ALL
    Ra Larson
    Department of Medicine and Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
    Bone Marrow Transplant 42:S18-S24. 2008
    ..However, Allo-HCT is recommended in CR1 for patients with high-risk ALL, for those in a second CR (CR2) and for certain other subsets of patients with this disease...
  8. ncbi request reprint Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
    Richard A Larson
    Department of Medicine and Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Best Pract Res Clin Haematol 20:29-37. 2007
    ..Most importantly, the molecular and genetic differences that appear to determine the phenotype and the outcome of these patients need to be investigated further...
  9. pmc Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia
    Richard A Larson
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Chem Biol Interact 184:21-5. 2010
    ..Down-regulation of the miR-181 family contributes to an aggressive leukemia phenotype through mechanisms associated with the activation of pathways of innate immunity mediated by toll-like receptors and interleukin-1beta...
  10. ncbi request reprint Myelodysplasia: when to treat and how
    Richard A Larson
    Department of Medicine and Cancer Research Center, University of Chicago Pritzker School of Medicine, MC 2115, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Best Pract Res Clin Haematol 19:293-300. 2006
    ..However, it is necessary to assess each patient's disease individually and to evaluate prognostic factors, other treatment options, and the appropriateness and timing of transplantation...
  11. ncbi request reprint Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B
    R A Larson
    Section of Hematology Oncology, Department of Medicine and Cancer Research Center, University of Chicago, Chicago, Ilinois, USA
    Hematol Oncol Clin North Am 14:1367-79, x. 2000
    ..These protocols have enrolled all adult patients older than 15 years with ALL, without an upper age restriction, and did not exclude Philadelphia (Ph) chromosome-positive patients...
  12. ncbi request reprint Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
    Richard A Larson
    Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Cancer 104:1442-52. 2005
    ..In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML)...
  13. ncbi request reprint Therapy-related myeloid leukaemia: a model for leukemogenesis in humans
    Richard A Larson
    Section of Hematology Oncology, Department of Medicine and Cancer Research Center, University of Chicago, MC 2115, 5341 S Maryland Avenue, Chicago, IL 60637, USA
    Chem Biol Interact 153:187-95. 2005
    ..Establishing the molecular pathways involved in t-AML may facilitate the identification of selectively expressed genes that can be exploited for the development of targeted therapies...
  14. ncbi request reprint Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B
    Richard A Larson
    Department of Medicine and Cancer Research Center, University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 12:3556s-63s. 2006
    ....
  15. ncbi request reprint Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
    K R Rai
    Cancer and Leukemia Group B, Chicago, USA
    N Engl J Med 343:1750-7. 2000
    ..We compared the efficacy of fludarabine with that of chlorambucil in the primary treatment of chronic lymphocytic leukemia...
  16. ncbi request reprint Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome
    Koen Van Besien
    Section of Hematology Oncology, Department of Health Studies, University of Chicago, IL, USA
    J Clin Oncol 23:5728-38. 2005
    ....
  17. ncbi request reprint Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia
    R A Larson
    Section of Hematology Oncology, Department of Medicine, Cancer Research Center of the University of Chicago, Chicago, IL, USA
    Blood 94:803-7. 1999
    ..Homozygotes and heterozygotes (who are at risk for treatment-induced mutation or loss of the remaining wild-type allele in their hematopoietic stem cells) may be particularly vulnerable to leukemogenic changes induced by carcinogens...
  18. ncbi request reprint Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
    R A Larson
    Department of Medicine, University of Chicago, Chicago, IL 60637 1470, USA
    Leukemia 16:1627-36. 2002
    ..Mylotarg is an effective treatment for older patients with CD33-positive AML in first relapse and has acceptable toxicity...
  19. pmc Myeloid leukemia after hematotoxins
    R A Larson
    Department of Medicine, University of Chicago, Illinois 60637 1470, USA
    Environ Health Perspect 104:1303-7. 1996
    ..Therapy-related leukemias with 11q23 or 21q22 rearrangements, inv(16) or t(15;17), have a more favorable response to treatment and a clinical course similar to their de novo counterparts...
  20. ncbi request reprint A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111
    R A Larson
    University of Chicago Medical Center, Chicago, IL 60637 1470, USA
    Blood 92:1556-64. 1998
    ..7 and 1.8 years, respectively). Adults who received intensive chemotherapy for ALL benefited from G-CSF treatment, but its use did not markedly affect the ultimate outcome...
  21. ncbi request reprint A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211
    J C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Leukemia 17:323-7. 2003
    ..Cladribine has modest clinical activity and considerable toxicity in a very selected group of patients with fludarabine-refractory CLL lacking pre-treatment neutropenia and thrombocytopenia...
  22. ncbi request reprint Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning
    J Kline
    Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Bone Marrow Transplant 37:307-10. 2006
    ..CMV prophylaxis with pre-transplant ganciclovir and high-dose valacyclovir after engraftment appears effective in preventing the excessive incidence of CMV infection after alemtuzumab-based conditioning regimens...
  23. ncbi request reprint Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?
    R A Larson
    Department of Medicine and Cancer Research Center, Section of Hematology Oncology, The University of Chicago, IL 60637, USA
    Leukemia 17:488-91. 2003
  24. ncbi request reprint Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q)
    F Lai
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Genomics 71:235-45. 2001
    ..The development of a transcription map will facilitate the molecular cloning of a myeloid leukemia suppressor gene on 5q...
  25. pmc Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases
    M M Le Beau
    Section of Hematology Oncology, University of Chicago, IL 60637 1470
    Proc Natl Acad Sci U S A 90:5484-8. 1993
    ..8 megabases. This cytogenetic map of 5q31, together with the molecular characterization of the critical region, will facilitate the identification of a putative tumor-suppressor gene in this band...
  26. ncbi request reprint P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults
    J E Kolitz
    Cancer and Leukemia Group B, Chicago, IL, USA
    Ann Hematol 83:S103-4. 2004
  27. ncbi request reprint Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes
    P Kebriaei
    Department of Medicine and Cancer Research Center, Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    Bone Marrow Transplant 35:965-70. 2005
    ..These data support an association between pre-transplant disease burden and poor outcome after SCT...
  28. doi request reprint Auto-SCT for AML in second remission: CALGB study 9620
    C A Linker
    Department of Medicine, University of California, San Francisco, CA 94143, USA
    Bone Marrow Transplant 44:353-9. 2009
    ..We conclude that this two-step approach to autologous transplantation produces good CD34+ mobilization and that this approach has cured some patients. Results in patients with APL are especially promising...
  29. ncbi request reprint The U.S. trials in adult acute lymphoblastic leukemia
    R A Larson
    Department of Medicine, Cancer Research Center, The University of Chicago, Chicago, Illinois, USA
    Ann Hematol 83:S127-8. 2004
  30. ncbi request reprint Current use and future development of gemtuzumab ozogamicin
    R A Larson
    University of Chicago, Chicago, IL 60637, USA
    Semin Hematol 38:24-31. 2001
    ..Additional studies are currently evaluating gemtuzumab ozogamicin in combination with, or as an alternative to, other standard AML chemotherapy...
  31. ncbi request reprint Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia
    S R Cataland
    Section of Hematology/Oncology, Department of Medicine and the Cancer Research Center, University of Chicago, Chicago, IL 60637-1470, USA
    Leuk Lymphoma 41:297-307. 2001
    ..The Cancer and Leukemia Group B is presently evaluating the efficacy of this regimen in a large phase II trial (CALGB study 19802)...
  32. ncbi request reprint Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002
    R A Larson
    Section of Hematology Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Leukemia 17:2358-82. 2003
    ..Clearly, over the past 25 years, molecular biology and biotechnology has provided the hematologist/oncologist novel bullets in their arsenal that will allow treatment by design in leukemia...
  33. ncbi request reprint High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3337-43. 2007
    ..To validate ERG overexpression as an adverse predictor and assess its prognostic value in the context of other molecular markers in cytogenetically normal (CN) -acute myeloid leukemia (AML)...
  34. pmc Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
    Daniel J DeAngelo
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:5136-42. 2007
    ..The 1-year overall survival was 28% (95% CI, 15%, 43%). Nelarabine is well tolerated and has significant antitumor activity in relapsed or refractory T-ALL and T-LBL...
  35. pmc Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study
    Susan P Whitman
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43240, USA
    Blood 109:5164-7. 2007
    ..5-7.7 years). Intensive consolidation therapy that included autologous peripheral stem-cell transplantation during CR1 may have contributed to the better outcome of this historically poor-prognosis group of CN-AML patients with MLL-PTD...
  36. ncbi request reprint Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
    John C Byrd
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus 43210 1240, USA
    Blood 100:4325-36. 2002
    ....
  37. doi request reprint Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107
    Meir Wetzler
    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 49:1274-8. 2008
    ..Although the combination of oblimersen and IM is safe and feasible, we did not observe clinical benefit in these patients with imatinib-resistant CML using these doses and schedule...
  38. ncbi request reprint Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant
    Zeba N Singh
    Section of Hematopathology, Department of Pathology, University of Chicago, Chicago, IL 60637, USA
    Am J Clin Pathol 127:197-205. 2007
    ..We found only a borderline difference in median survival of patients with an initial t-MDS diagnosis compared with patients with an initial t-AML diagnosis...
  39. ncbi request reprint Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Brian J Druker
    Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    N Engl J Med 355:2408-17. 2006
    ..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy...
  40. ncbi request reprint End points to establish the efficacy of new agents in the treatment of acute leukemia
    Frederick R Appelbaum
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 109:1810-6. 2007
    ..In this report, we present the results of that effort...
  41. ncbi request reprint Nelarabine in the treatment of refractory T-cell malignant diseases
    Justin Kline
    Section of Hematology Oncology, Department of Medicine and Cancer Research Center, University of Chicago, Chicago, IL, USA
    Expert Opin Pharmacother 7:1791-9. 2006
    ..This article describes the development, pharmacology, toxicity and clinical activity of nelarabine, as well as discusses its potential role in the treatment of T-cell haematological malignancies...
  42. ncbi request reprint Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:3904-11. 2006
    ..To analyze the prognostic impact of mutated KIT (mutKIT) in core-binding factor acute myeloid leukemia (AML) with inv(16)(p13q22) and t(8;21)(q22;q22)...
  43. pmc Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia
    Zhijian Qian
    Section of Hematology Oncology and the Cancer Research Center, University of Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 99:14925-30. 2002
    ..Establishing the molecular pathways involved in t-AML may facilitate the identification of selectively expressed genes that can be exploited for the development of urgently needed targeted therapies...
  44. ncbi request reprint Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
    Philipp Le Coutre
    Campus Virchow Klinikum, Charite Universitatsmedizin, Berlin, Germany
    Blood 111:1834-9. 2008
    ..In conclusion, nilotinib is an effective and well-tolerated treatment in imatinib-resistant and -intolerant CML-AP. This trial is registered at www.clinicaltrials.gov as NCT00384228...
  45. ncbi request reprint Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, USA
    Blood 101:6-14. 2003
    ..Rituximab administered concurrently with fludarabine in previously untreated CLL patients demonstrates marked clinical efficacy and acceptable toxicity. Phase 3 studies using this combination approach for patients with CLL are warranted...
  46. doi request reprint Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia
    Olatoyosi M Odenike
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637 1470, USA
    Invest New Drugs 26:233-9. 2008
    ..The primary objective of the study was to establish the maximum tolerated dose of 3-AP when given in combination with a fixed dose of cytarabine...
  47. ncbi request reprint Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
    Charles L Sawyers
    Department of Medicine and Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
    Blood 99:3530-9. 2002
    ..Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs...
  48. ncbi request reprint Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011
    Vicki A Morrison
    Section of Hematology Oncology, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    J Clin Oncol 20:3878-84. 2002
    ..A series of patients enrolled onto an intergroup CLL trial were examined for this complication...
  49. pmc Therapy-related myeloid leukemia
    Lucy A Godley
    Department of Medicine and Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 35:418-29. 2008
    ..Ultimately, this knowledge could influence initial treatment strategies with the goal of decreasing the incidence of this serious complication...
  50. pmc Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720
    Maria R Baer
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    J Clin Oncol 26:4934-9. 2008
    ..Cancer and Leukemia Group B (CALGB) 9720 evaluated subcutaneous low-dose recombinant interleukin-2 (rIL-2) maintenance immunotherapy as a strategy for prolonging remission in older patients with acute myeloid leukemia (AML)...
  51. pmc Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study
    Andreas Neubauer
    Department for Hematology, Oncology and Immunology, Philipps University, Marburg, Germany
    J Clin Oncol 26:4603-9. 2008
    ..RAS mutations occur in 12% to 27% of patients with acute myeloid leukemia (AML) and enhance sensitivity to cytarabine in vitro. We examined whether RAS mutations impact response to cytarabine in vivo...
  52. pmc What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
    Wendy Stock
    Section of Hematology Oncology, Department of Medicine, University of Chicago and University of Chicago Cancer Research Center, IL 60637, USA
    Blood 112:1646-54. 2008
    ..Based on these observations, a prospective study for AYAs with ALL using the more successful approach of the CCG has been initiated...
  53. ncbi request reprint A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases
    Olatoyosi M Odenike
    Section of Hematology Oncology, Department of Medicine, University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637 1470, USA
    Cancer Chemother Pharmacol 54:553-61. 2004
    ....
  54. doi request reprint A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia
    Wendy Stock
    Section of Hematology Oncology, University of Chicago Cancer Research Center, 5841 S Maryland, M C 2115, Chicago, IL 60637, USA
    Invest New Drugs 26:331-8. 2008
    ..No correlation was observed between the development of DLT and pharmacokinetics. The RTPD is 1,750 mg. XK469R induced hematological responses in patients with refractory leukemia at tolerable doses...
  55. doi request reprint Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products
    Melinda K Gordon
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
    Leuk Lymphoma 49:531-7. 2008
    ..No patient has yet required transplantation. With median follow-up of 18 months, all patients remain in CCyR and 9 of 16 (54%) have undetectable BCR-ABL in the most recent blood and marrow sample...
  56. ncbi request reprint Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420
    Sherif S Farag
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 8:2812-9. 2002
    ..The purpose of the study is to investigate the tolerability of interleukin 2 (IL-2) after intensive chemotherapy in elderly acute myeloid leukemia (AML) patients in first complete remission (CR)...
  57. ncbi request reprint Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials
    Lydia Roy
    Department of Oncology Hematology and Cell Therapy, EA 3805, CHU La Miletrie, 2 rue de la Miletrie, 86021 Poitiers Cedex, France
    Blood 108:1478-84. 2006
    ..In conclusion, within the limitation of this historical comparison, there is a survival advantage from first-line therapy with imatinib over IFN/Ara-C...
  58. ncbi request reprint Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
    Sonali M Smith
    Section of Hematology Oncology, Department of Medicine, MC2115, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Blood 102:43-52. 2003
    ..0001). Median survival time after diagnosis of t-MDS/t-AML was 8 months; survival at 5 years was less than 10%. These data confirm and extend previous associations between clinical, morphologic, and cytogenetic findings in t-MDS/t-AML...
  59. ncbi request reprint Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, P O Box 428, Houston, TX 77030, USA
    Leuk Res 27:1091-6. 2003
    ..Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML...
  60. ncbi request reprint Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 11:4176-81. 2005
    ..We sought to determine if flavopiridol has activity in previously treated CLL using two schedules of administration...
  61. ncbi request reprint Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity
    Guido Marcucci
    Division of Hematology Oncology, The Comprehensive Cancer Center, The Ohio State University, 433A Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:3404-11. 2005
    ..Herein, we investigated the feasibility of this approach in untreated elderly AML patients by administering oblimersen sodium (G3139), an 18-mer phosphorothioate antisense to Bcl-2, during induction and consolidation treatments...
  62. pmc Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222
    Joseph O Moore
    University of Chicago, MC 2115, 5841 S Maryland Ave, Chicago, IL 60637, USA
    Blood 105:3420-7. 2005
    ..Toxicity was greater with multiagent chemotherapy. These 2 postremission regimens produced similar outcomes...
  63. ncbi request reprint Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies
    Todd M Zimmerman
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    J Clin Oncol 22:4816-22. 2004
    ..Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, has activity in hematologic malignancies, but the dose required to achieve the proposed biologic end point, inhibition of farnesylation, is unknown...
  64. ncbi request reprint Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, A433A Starling Loving Hall, 320 W Tenth Avenue, Columbus, OH 43210, USA
    J Clin Oncol 23:482-93. 2005
    ..Evaluate the outcome of induction and postremission therapy in adults younger than 60 years with normal cytogenetics acute myeloid leukemia (AML)...
  65. ncbi request reprint Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B
    Jonathan E Kolitz
    Don Monti Division of Oncology and Division of Hematology, Department of Medicine, North Shore University Hospital, New York University School of Medicine, NY 11030, USA
    J Clin Oncol 22:4290-301. 2004
    ..Clinical rather than pharmacokinetic end points were used to develop two induction therapies containing drugs susceptible to Pgp-mediated efflux and associated with comparable toxicities at the maximum-tolerated doses...
  66. ncbi request reprint Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature
    William Blum
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus 43210, USA
    Cancer 101:1420-7. 2004
    ..Acute myeloid leukemia (AML) with t(6;11)(q27;q23) is a well established but rare entity, and few studies have reported the full clinical, hematologic, and outcome data of patients with this disease...
  67. ncbi request reprint Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461
    Guido Marcucci
    Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 22:2410-8. 2004
    ..To our knowledge, ours is the first relatively large study evaluating the usefulness of CRc attained immediately following induction chemotherapy...
  68. ncbi request reprint Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 105:49-53. 2005
    ..Confirmation of these findings will require a prospective randomized trial comparing fludarabine and rituximab to fludarabine...
  69. ncbi request reprint Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B
    Meir Wetzler
    Department of Medicine, Leukemia Section, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Br J Haematol 124:275-88. 2004
    ..02). It will be of interest to see if newly diagnosed t(9;22)-positive adult ALL patients with these and other secondary aberrations respond differently to treatment regimens that include imatinib mesylate...
  70. ncbi request reprint Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461
    John C Byrd
    Division of Hematology and Oncology and the Comprehensive Cancer Center, The Ohio State University, B302A Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210 1240, USA
    J Clin Oncol 22:1087-94. 2004
    ..To study the impact of repetitive (three to four courses) versus a single course of high-dose cytarabine (HDAC) consolidation therapy on outcome of patients with acute myeloid leukemia (AML) and inv(16)(p13q22) or t(16;16)(p13;q22)...
  71. ncbi request reprint Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study
    Elizabeth A Hahn
    Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, 1001 University Pl, Ste 100, Evanston, IL 60201, USA
    J Clin Oncol 21:2138-46. 2003
    ..Quality of life (QOL) outcomes in patients with chronic myeloid leukemia (CML) were evaluated in an international phase III study...
  72. ncbi request reprint Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, A433B Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:5705-17. 2005
    ..Therefore, we sought to determine whether these two cytogenetic groups should also be considered separate entities from a clinical standpoint...
  73. ncbi request reprint Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples
    Wendy Stock
    University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    Int J Oncol 28:1099-103. 2006
    ..Based on these results, we caution against interchanging BM with PB sampling for MRD monitoring during treatment of CML since this may lead to misinterpretation of treatment results...
  74. pmc Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 108:63-73. 2006
    ..Patients with complex > or = 5 appear to benefit minimally from current treatment and are better suited for investigational therapy or supportive care...
  75. ncbi request reprint Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    Stephen G O'Brien
    University of Newcastle, Newcastle, United Kingdom
    N Engl J Med 348:994-1004. 2003
    ..We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML...
  76. ncbi request reprint Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group
    William R Friedenberg
    Department of Hematology Oncology, Guthrie Foundation for Education and Research, Sayre, Pennsylvania, USA
    Cancer 106:830-8. 2006
    ....
  77. pmc Gene expression profiles in acute myeloid leukemia with common translocations using SAGE
    Sanggyu Lee
    Department of Medicine, University of Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 103:1030-5. 2006
    ....
  78. ncbi request reprint Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013
    Richard T Silver
    Weill Medical College of Cornell University, Division of Hematology Oncology, 525 E 68th St Box 581, New York, NY 10021, USA
    Leuk Lymphoma 44:39-48. 2003
    ..01) using a landmark analysis at 18 months. This intermittent schedule of rIFNalpha-2b/ara-C has a high response rate in patients with CML with acceptable toxicity...
  79. ncbi request reprint Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy
    John C Byrd
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:437-43. 2006
    ..1), and p53 mutations. To date, the impact of these same prognostic factors have not been examined relative to treatment outcome with chemoimmunotherapy...
  80. ncbi request reprint Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review
    Justin P Kline
    Department of Medicine, Cancer Research Center, University of Chicago, Chicago, IL, USA
    Expert Opin Pharmacother 6:2711-8. 2005
    ..This article describes the development, pharmacology, toxicity and clinical activity of clofarabine, as well as discuss its potential role in the treatment of acute leukaemia...
  81. ncbi request reprint Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus OH 43210, USA
    J Clin Oncol 23:9234-42. 2005
    ..To test the prognostic significance of ETS-related gene (ERG) expression in cytogenetically normal primary acute myeloid leukemia (AML)...
  82. ncbi request reprint The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review
    Theresa Hahn
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Biol Blood Marrow Transplant 11:823-61. 2005
    ....
  83. ncbi request reprint Adult ALL: where are we and where are we going?
    Richard A Larson
    University of Chicago, IL, USA
    Clin Adv Hematol Oncol 2:342-4. 2004
  84. ncbi request reprint BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study
    Claudia D Baldus
    The Ohio State University, Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    Blood 102:1613-8. 2003
    ..7, 2.6, and 2.2. We conclude that high BAALC expression predicts an adverse prognosis and may define an important risk factor in AML with normal cytogenetics...
  85. ncbi request reprint RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7
    Lucy E Side
    Department of Pediatrics, University of California, San Francisco, California 94143, USA
    Genes Chromosomes Cancer 39:217-23. 2004
    ..RAS and FLT3 mutations, which are thought to stimulate the proliferation of leukemia cells, appear to be less common in t-MDS/t-AML than in de novo AML, whereas TP53 mutations are more frequent...